Join the club for FREE to access the whole archive and other member benefits.

Longevity Vision Fund joins Series B funding for Sigilon Therapeutics


Key points from article :

Longevity Vision Fund is excited to announce its investment into Sigilon Therapeutics.

It joined the Series B financing total of $80.3 million led by Flagship Pioneering.

The financing round brings Sigilon’s total funding to more than $195 million.

The funding will support the first-in-human clinical trial of Sigilon.

For novel encapsulated cell therapy for hemophilia A.

Sigilon has a global collaboration with Eli Lilly.

To develop encapsulated cell therapies for potential treatment of type 1 diabetes.

Sigilon’s technology has a great potential to liberate patients from treatment challenges.

Its lead investigational therapy for hemophilia A is called SIG-001.

It has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).

Expected to initiate a first-in-human clinical trial of SIG-001 in the first half of 2020.

To support human clinical trial of novel encapsulated cell therapy for hemophilia A

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Professor, Chemical Engineering and Institute for Medical Engineering and Science, MIT


American pharmaceutical company


Ensuring safety of drugs, medical supplies and food which is used daily.


Life sciences firm


$100M life extension-focused investment fund


Private land-grant research university


American chemical engineer, scientist, Institute Professor at MIT

Company Representative

Author and Longevity investor and visionary.


Biotechnology company